Brain metastases in patients with ovarian cancer

References

• Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system. J Clin Oncol. 2004;22(14):2865–2872.
   PubMed Web of Science ®Google Scholar
• Schouten LJ, Rutten J, Huveneers HA, et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, Colon, kidney, and lung and melanoma. Cancer. 2002;94(10):2698–2705.
   PubMed Web of Science ®Google Scholar
• Cagney DN, Martin AM, Catalano PJ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19(11):1511–1521.
   PubMed Web of Science ®Google Scholar
• Habbous S, Forster K, Darling G, et al. Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study. Neurooncol Adv. 2021;3(1):vdaa178.
   PubMedGoogle Scholar
• Ali S, Gorska Z, Duchnowska R, et al. Molecular profiles of brain metastases: a focus on heterogeneity. Cancers. 2021;13(11):2645.
   PubMed Web of Science ®Google Scholar
• Steindl A, Brunner TJ, Heimbach K, et al. Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years. Eur J Cancer. 2022;162:170–181.
   PubMed Web of Science ®Google Scholar
• Bertolini F, Spallanzani A, Fontana A, et al. Brain metastases: an overview. CNS Oncol. 2015;4(1):37–46.
   PubMedGoogle Scholar
• Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003;21(13):2529–2536.
   PubMed Web of Science ®Google Scholar
• Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004;22(1):157–165.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Mesko S, Li J, et al. Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol. 2020;38(32):3773–3784.
   PubMed Web of Science ®Google Scholar
• Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271–3277.
   PubMed Web of Science ®Google Scholar
• Martin AM, Cagney DN, Catalano PJ, et al. Brain metastases in newly diagnosed breast cancer: a population-based study. JAMA Oncol. 2017;3(8):1069–1077.
   PubMed Web of Science ®Google Scholar
• Limon D, Gal O, Gordon N, et al. Brain metastasis in gastroesophageal adenocarcinoma and HER2 status. J Neurooncol. 2018;138(2):315–320.
   PubMed Web of Science ®Google Scholar
• Iuchi T, Shingyoji M, Itakura M, et al. Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations. Int J Clin Oncol. 2015;20(4):674–679.
   PubMed Web of Science ®Google Scholar
• Rangachari D, Yamaguchi N, VanderLaan PA, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015;88(1):108–111.
   PubMed Web of Science ®Google Scholar
• Nabors LB, Portnow J, Ahluwalia M, et al. Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(11):1537–1570.
   PubMed Web of Science ®Google Scholar
• Tsao MN, Rades D, Wirth A, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2012;2(3):210–225.
   PubMedGoogle Scholar
• Tallet AV, Azria D, Barlesi F, et al. Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol. 2012;7:77.
   PubMed Web of Science ®Google Scholar
• Brown P, Asher A, Ballman K, et al. BMET-05: NCCTG N0574 (ALLIANCE): a phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. Neuro Oncol. 2015;17(Suppl 5):v45–v46.
   PubMed Web of Science ®Google Scholar
• Tsao M, Xu W, Sahgal A. A Meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer. 2012;118(9):2486–2493.
   PubMed Web of Science ®Google Scholar
• Mikkelsen T, Paleologos NA, Robinson PD, et al. The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):97–102.
   PubMed Web of Science ®Google Scholar
• Sirven JI, Wingerchuk DM, Drazkowski JF, et al. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc. 2004;79(12):1489–1494.
   PubMed Web of Science ®Google Scholar
• Tremont-Lukats IW, Ratilal BO, Armstrong T, et al. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev. 2008;16(2):CD004424.
   Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA A Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66–71.
   PubMed Web of Science ®Google Scholar
• Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265(5181):2088–2090.
   PubMed Web of Science ®Google Scholar
• Walsh CS. Two decades beyond BRCA1/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol Oncol. 2015;137(2):343–350.
   PubMed Web of Science ®Google Scholar
• Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032–18037.
   PubMed Web of Science ®Google Scholar
• Metcalfe KA, Poll A, Royer R, et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol. 2010;28(3):387–391.
   PubMed Web of Science ®Google Scholar
• Casanova DR. Beckmann and ling’s obstetrics and gynecology. 8th ed. Philadelphia (PA): LWW; 2018.
   Google Scholar
• Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14.
   PubMed Web of Science ®Google Scholar
• Xu K, Yang S, Zhao Y. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis. Oncotarget. 2017;8(1):285–302.
   PubMedGoogle Scholar
• Haunschild CE, Tewari KS. The current landscape of molecular profiling in the treatment of epithelial ovarian cancer. Gynecol Oncol. 2021;160(1):333–345.
   PubMed Web of Science ®Google Scholar
• Geisler JP, Geisler HE. Brain metastases in epithelial ovarian carcinoma. Gynecol Oncol. 1995;57(2):246–249.
   PubMed Web of Science ®Google Scholar
• Anupol N, Ghamande S, Odunsi K, et al. Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases. Gynecol Oncol. 2002;85(3):487–492.
   PubMed Web of Science ®Google Scholar
• Gray S, Khor XY, Yiannakis D. Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases. BMJ Case Rep. 2019;12(8):e230738.
   PubMedGoogle Scholar
• O'Sullivan CC, Davarpanah NN, Abraham J, et al. Current challenges in the management of breast cancer brain metastases. Semin Oncol. 2017;44(2):85–100.
   PubMed Web of Science ®Google Scholar
• Tao M, Cheng J, Wu X. Niraparib as maintenance therapy in germline ATM-mutated and somatic BRCA2-mutated ovarian cancer with brain metastases: a case report and literature review. Onco Targets Ther. 2020;13:12979–12986.
   PubMed Web of Science ®Google Scholar
• Diossy M, Reiniger L, Sztupinszki Z, et al. Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors. Ann Oncol. 2018;29(9):1948–1954.
   PubMed Web of Science ®Google Scholar
• Mansouri A, Padmanaban V, Aregawi D, et al. VEGF and immune checkpoint inhibition for prevention of brain metastases: systematic review and meta-analysis. Neurology. 2021;97(15):e1484–e1492.
   Web of Science ®Google Scholar
• Borella F, Bertero L, Morrone A, et al. Brain metastases from ovarian cancer: current evidence in diagnosis, treatment, and prognosis. Cancers. 2020;12(8):2156.
   Web of Science ®Google Scholar
• Li X, Yang Q, Chen M, et al. Differences between primary peritoneal serous carcinoma and advanced serous ovarian carcinoma: a study based on the SEER database. J Ovarian Res. 2021;14(1):40.
   PubMed Web of Science ®Google Scholar
• Stasenko M, Cybulska P, Feit N, et al. Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. Gynecol Oncol. 2019;154(1):144–149.
   PubMed Web of Science ®Google Scholar
• Ratner E, Bala M, Louie-Gao M, et al. Increased risk of brain metastases in ovarian cancer patients with BRCA mutations. Gynecol Oncol. 2019;153(3):568–573.
   PubMed Web of Science ®Google Scholar
• Jernigan AM, Mahdi H, Rose PG. Epithelial ovarian cancer metastatic to the central nervous system and a family history concerning for hereditary breast and ovarian cancer-a potential relationship. Int J Gynecol Cancer. 2015;25(7):1232–1238.
   PubMed Web of Science ®Google Scholar
• Takeshita S, Todo Y, Furuta Y, et al. Prognostic factors for patients with brain metastasis from gynecological cancer: a significance of treatment-free interval of more than 6 months. Jpn J Clin Oncol. 2017;47(7):604–610.
   PubMed Web of Science ®Google Scholar
• Pakneshan S, Safarpour D, Tavassoli F, et al. Brain metastasis from ovarian cancer: a systematic review. J Neurooncol. 2014;119(1):1–6.
   PubMed Web of Science ®Google Scholar
• Piura E, Piura B. Brain metastases from ovarian carcinoma. ISRN Oncol. 2011;2011:527453.
   PubMedGoogle Scholar
• Morgan AJ, Giannoudis A, Palmieri C. The genomic landscape of breast cancer brain metastases: a systematic review. Lancet Oncol. 2021;22(1):e7–e17.
   PubMed Web of Science ®Google Scholar
• Keskin S, Kucucuk S, Ak N, et al. Survival impact of optimal surgical cytoreduction in recurrent epithelial ovarian cancer with brain metastasis. Oncol Res Treat. 2019;42(3):101–106.
   PubMed Web of Science ®Google Scholar
• Nasu K, Satoh T, Nishio S, et al. Clinicopathologic features of brain metastases from gynecologic malignancies: a retrospective study of 139 cases (KCOG-G1001s trial). Gynecol Oncol. 2013;128(2):198–203.
   PubMed Web of Science ®Google Scholar
• Bahat Z, Cakmak VA, Cakir E. Brain metastasis from ovarian carcinoma: analysis of eight cases from a single radiotherapy center. Taiwan J Obstet Gynecol. 2020;59(5):711–717.
   PubMed Web of Science ®Google Scholar
• Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys. 1994;29(4):711–717.
   PubMed Web of Science ®Google Scholar
• Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996;78(7):1470–1476.
   PubMed Web of Science ®Google Scholar
• Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280(17):1485–1489.
   PubMed Web of Science ®Google Scholar
• Patchell RA, Regine WF. The rationale for adjuvant whole brain radiation therapy with radiosurgery in the treatment of single brain metastases. Technol Cancer Res Treat. 2003;2(2):111–115.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Drew Y, Kristeleit RS. Homologous recombination deficiency and ovarian cancer. Eur J Cancer. 2016;60:49–58.
   PubMed Web of Science ®Google Scholar
• Radu MR, Prădatu A, Duică F, et al. Ovarian cancer: biomarkers and targeted therapy. Biomedicines. 2021;9(6):693.
   PubMed Web of Science ®Google Scholar